Last $1,174 MXN
Change Today 0.00 / 0.00%
Volume 0.0
NVSN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
Frankfurt
SIX Swiss Ex
As of 4:08 PM 10/17/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-adr (NVSN) Snapshot

Open
$1,166
Previous Close
$1,174
Day High
$1,174
Day Low
$1,166
52 Week High
10/1/14 - $1,255
52 Week Low
12/18/13 - $1,001
Market Cap
3.2T
Average Volume 10 Days
2.6K
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
02/27/14
P/E TM
--
Dividend
$2.71
Dividend Yield
3.13%
Current Stock Chart for NOVARTIS AG-ADR (NVSN)

novartis ag-adr (NVSN) Details

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. The company’s Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company’s Vaccines and Diagnostics division provides preventive human vaccines. Its Consumer Health division offers over-the-counter medicines comprising readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. The company distributes its OTC products through various channels, such as food, drug, and mass retail outlets, as well as pharmacies; and Animal Health products directly and through wholesalers of veterinary products. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

135,000 Employees
Last Reported Date: 07/17/14
Founded in 1895

novartis ag-adr (NVSN) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.3.1M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: SFr.747.1K
President of Institutes for Biomedical Resear...
Total Annual Compensation: $1.9M
Division Head of Novartis Pharmaceuticals and...
Total Annual Compensation: $2.0M
Division Head of Animal Health and Member of ...
Total Annual Compensation: SFr.1.4M
Compensation as of Fiscal Year 2013.

novartis ag-adr (NVSN) Key Developments

FDA Advisory Committee Unanimously Recommends Approval of Novartis's AIN457 (Secukinumab) for Patients with Moderate-To-Severe Plaque Psoriasis

Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) voted 7 to 0 to support the approval of AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body) or phototherapy (light therapy). The DODAC based its recommendation on the safety and efficacy outcomes from 10 psoriasis Phase II/III clinical studies which included nearly 4,000 patients with moderate-to-severe plaque psoriasis.

Novartis Announces CTL019 Data Published in NEJM Demonstrating Efficacy in Certain Patients with Acute Lymphoblastic Leukemia

Novartis and the University of Pennsylvania’s Perelman School of Medicine (Penn) announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine (NEJM) evaluating the efficacy and safety of CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). The studies, conducted by Penn, demonstrated that 27 of 30 pediatric and adult patients, or 90%, experienced complete remissions with the investigational chimeric antigen receptor (CAR) therapy CTL019. These data build on earlier research findings and are part of two pilot clinical studies that demonstrated sustained remissions of up to two years in pediatric and adult patients with r/r ALL. Median follow-up was just over six months, with event-free survival of 67% and overall survival of 78%. Probability of six-month CTL019 persistence was 68% and CTL019-modified T cells were detectable in the blood by flow cytometry for up to 11 months. Sustained remissions were seen in 15 patients and were associated with CAR T cell persistence and B cell aplasia. Updated results have been submitted for presentation at a medical congress taking place later in 2014.

Novartis To Sell Unit Being Built In Pernambuco

Novartis AG (SWX:NOVN) will no longer pursue the project being built in Pernambuco. Valor has learned that Novartis is seeking companies interested in taking over the unit, which is being built in Jaboatão dos Guararapes. One company possibly interested in acquiring the plant would be GlaxoSmithKline plc (LSE:GSK).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVSN:MM $1,174.00 MXN 0.00

NVSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $103.13 USD +0.50
Merck & Co Inc $57.61 USD +0.98
Pfizer Inc $29.11 USD +0.51
Roche Holding AG SFr.278.00 CHF -1.40
Procter & Gamble Co/The $85.16 USD +1.93
View Industry Companies
 

Industry Analysis

NVSN

Industry Average

Valuation NVSN Industry Range
Price/Earnings 24.2x
Price/Sales 3.7x
Price/Book 3.1x
Price/Cash Flow 25.0x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.